Morningside Ventures dina iki ngumumake peluncuran Adiso Therapeutics, perusahaan bioteknologi tahap klinis sing ngembangake saluran pipa terapi novel sing nargetake penyakit inflamasi. Morningside wis mbiayai rencana pangembangan Adiso nganti saiki, kanthi rencana kanggo ndhukung pangembangan perusahaan kanthi cepet.
Adiso ngembangake saluran pipa inovatif saka molekul cilik kanthi mekanisme aksi anyar lan produk bioterapi urip galur tunggal (SS-LBP), ngupayakake indikasi timbal ing kolitis ulcerative (UC), lan infeksi C. difficile (CDI). Saliyane rong program Fase 1 (UC & CDI) lan program Fase 2 (UC), Adiso ngembangake program inflammasome novel ing fase penemuan sing wiwitane ditliti ing inflamasi ambegan, kanthi macem-macem wilayah terapeutik potensial sing bakal ditindakake.
Perusahaan iki dumadi saka 25 karyawan sing sadurunge, ing payung Morningside, kasil mbukak telung Investigational New Drug (IND) lan wis ngajokake akeh paten uga entuk US FDA Fast Track Designation, sing pungkasane nyebabake pembentukan Adiso. Adiso bakal makarya ing sangisore pimpinan Chief Executive Officer, Scott Megaffin. Pak Megaffin nduweni pengalaman industri luwih saka 30 taun lan rekor sukses ing peran kepemimpinan senior ing Bristol-Myers Squibb, Pfizer, Schering-Plough, Adolor, Onconova, lan Churchill. Paling anyar, Pak Megaffin njabat minangka CEO Adastra Pharmaceuticals, perusahaan pangembangan tahap klinis onkologi, ing ngendi dheweke nuntun perusahaan kasebut supaya sukses transaksi karo Cothera Bioscience ing Oktober 2021.
"Kabutuhan medis sing ora bisa ditindakake kritis ana kanggo terapi anyar sing ngarahake biologi ndasari penyakit inflamasi tanpa nyebabake imunosupresi sistemik," ujare Jason Dinges, Penasihat Teknologi Morningside lan Anggota Dewan Adiso. "Adiso sprinting metu saka gapura karo telung program klinis banget janjeni kanggo perawatan ulcerative colitis lan Nyegah saka ambalan CDI. Kita percaya yen ing pimpinan Scott lan karo tim pangembang obat sing duwe bakat, Adiso wis siyap sukses.
"Ing Adiso, kita ngatasi penyakit inflamasi kanthi macem-macem mekanisme lan pendekatan sing wani. Kita mbayangake kasunyatan anyar kanggo pasien, nggunakake kemajuan terapeutik inflamasi sing dijanjekake bakal ngetutake ulang sistem kekebalan host, supaya penyakit inflamasi sing ndasari ora overactivated utawa pasien dadi immunocompromised, "ujare Scott Megaffin, CEO Adiso Therapeutics. . "Aku diajeni bisa mimpin tim sing luar biasa, kelas donya, lan khusus ing Adiso ing pangembangan terapi sing unik iki sing dirancang kanggo nyegah disregulasi sing disebabake dening inflamasi."
Mustafa A. Noor, MD, FACP uga wis gabung karo tim pimpinan Adiso. Dr. Noor njupuk posisi Kepala Petugas Medis, nggawa luwih saka 20 taun keahlian pangembangan obat ing pirang-pirang wilayah terapeutik ing pirang-pirang tahap awal nganti pertengahan lan perusahaan global kalebu AMAG Pharmaceuticals, Akcea Therapeutics, Ipsen, Pfizer, Glaxo-Smith Kline , lan Bristol Myers Squibb.
"Disregulasi inflamasi minangka pusat kanggo akeh penyakit serius lan karusakan sing nyebabake kacilakan kanggo kesehatan lan kesejahteraan pasien. Pilihan perawatan saiki ora cukup kanggo mungkasi kemajuan penyakit lan ningkatake kualitas urip kanthi cara sing aman lan migunani, "ujare Dr. Noor, CMO saka Adiso Therapeutics. "Atribut unik saka portofolio Adiso kanggo perawatan gangguan inflamasi duweni potensi kanggo pungkasane dadi obat anyar sing penting kanggo pasien. Mbangun studi klinis praklinis lan awal sing sukses nganti saiki, aku ngarepake mimpin tahap pangembangan klinis portofolio sabanjure kanthi tim pangembang klinis sing berpengalaman.
APA sing kudu dijupuk saka ARTIKEL INI:
- We envision a new reality for patients, leveraging known advances of inflammatory therapeutics which promise to recalibrate the immune system of the host, so that the underlying inflammatory disease is neither overactivated nor does the patient becoming immunocompromised,”.
- Building on the successful preclinical and early clinical studies to date, I look forward to leading the next stages of clinical development of our portfolio with an experienced team of clinical developers.
- CDI) and a Phase 2 program (UC), Adiso is developing a novel inflammasome program in discovery phase which is being initially explored in respiratory inflammation, with multiple future potential therapeutic areas to pursue.
